Global Pars Planitis Treatment Market - 2023-2030

Global Pars Planitis Treatment Market - 2023-2030

Global pars planitis treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global pars planitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A persistent intermediate uveitis called pars planitis has not been connected with any systemic illness or infection. Although pars planitis patients rarely experience symptoms, they could mention floaters or impaired vision. There is typically no pain or photophobia.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like corticosteroids or immunosuppressives and boost the global pars planitis treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for pars planitis treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On July 3, 2023, the global biosimilars business of Viatris was recently acquired by Biocon Biologics, which has also obtained numerous biosimilar licenses in the United States, Europe, and more than 100 other nations. Biocon Biologics can now assist in supplying patients and medical professionals with additional accessible and inexpensive treatment alternatives thanks to the acquisition of Viatris' biosimilars business.

After five years of use in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a division of Biocon Ltd, announced that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), has become accessible to patients in the United States.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising pars planitis cases and increasing research for innovative treatment development will be a major factor driving the growth of the pars planitis treatment market.

Side effects associated with the pars planitis treatment drugs

Regardless of treatment, patients with pars planitis could be at a greater likelihood for getting multiple sclerosis and anti-TNF Drugs may predispose to demyelination. Therefore, utmost caution should be utilized and the risk-benefit ratio should be assessed before administering an anti-TNF drug to a patient with pars planitis.

Pars planitis has also been successfully treated with interferon, however side effects can include depression or suicidal thoughts. Cataracts and glaucoma are the side effects of steroids that are most frequently administered.

Segment Analysis

The global pars planitis treatment market is segmented based on drugs, route of administration, distribution channel and region.

Corticosteroids segment accounted for approximately 37% of market share

Prednisolone sodium phosphate or acetate topical treatment, both of which are 1%. Along with oral prednisone, periocular injections with corticosteroids are also beneficial. Treatment options include intravitreal injections of triamcinolone acetonide.

Steroid medications can be used to treat the majority of intermediate uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation.

On November 17, 2021, the U.S. Food and Drug Administration has given final approval to Aurobindo Pharma Limited's Abbreviated New Drug Application for Prednisone Tablets USP, 1mg. Prednisone Tablets USP, 1mg from Aurobindo Pharma are a reference-listed drug (RLD) identical to Meticorten Tablets from Schering Corp Sub Schering Plough Corp.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for pars planitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for pars planitis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different classes of drug, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of pars planitis treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global pars planitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for pars planitis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating pars planitis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global pars planitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for pars planitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global pars planitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments
• On March 21, 2023, the US Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) which is citrate-free of Sandoz's biosimilar Hyrimoz (adalimumab-adaz) injection, according to the company, a leader in generic drugs and biosimilars. The reference drug Humira* (adalimumab) covers seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, and plaque psoriasis. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat these conditions.
• On March 25, 2021, Omeprazole Prolonged Release Capsules, 20mg, a generic version of Prilosec, have been launched, according to Xiromed LLC, the generic branch of Insud Pharmaceuticals based in New Jersey. Proton pump inhibitors like Prilosec are prescribed for treating gastroesophageal reflux disease (GERD) in both adults and children as well as for treating duodenal and gastric ulcers in adults and maintaining the healing of erosive esophagitis.

Competitive Landscape

The major global players in the market include Teva Pharmaceutical Industries Ltd., AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim Pharmaceuticals, Inc. among others.

Why Purchase the Report?
• To visualize the global pars planitis treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pars planitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pars planitis treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies